There is an opioid overdose epidemic occurring right now in the United States. According to the Centers for Disease Control (CDC), the U.S. is in crisis mode as it responds to this epidemic that claimed the lives of more than 33,000 people in 2015 alone. While federal and state regulations have clamped down on how doctors prescribe opiates for their patients, the number of people battling opiate addiction and overdose remain extremely high. It is this crisis that has prompted bio-tech company, Health Advance, Inc. to seek new solutions to pain management and opiate addiction. One of those solutions is Polyoxyfen.
Polyoxyfen is an organic “medical food” combining a unique botanical blend that includes Kratom (Mitragyna Speciosa) and Kava extract with Ibuprofen. The result is a formula that aids in the production of the neurotransmitters that are responsible for managing inflammation and pain. Health Advance, Inc. is working to meet FDA regulatory requirements to have Polyoxyfen labeled as GRAS (Generally Recognized As Safe). Their goal is to legalize it for national distribution in the healthcare marketplace by the end of 2017 and market it as a safer alternative to opiates.
Kratom (Mitragyna speciosa) is a psychoactive plant that has been used since at least 1836 for medicinal purposes in Southeast Asian countries. More recently, kratom has become widely available in the West and is used for both recreational and medicinal purposes.
According to research, kratom is highly effective for opiate withdrawals. Due to it’s cross-tolerance with opiates, kratom is extensively used in New Zealand for detox treatment. Those who are addicted to opium are given kratom to smoke for six weeks and after then, opiate withdrawal symptoms are clearly noticed. Within this time period, dosage of kratom is slowly reduced.
Drugs that are classified as opiates include Oxycodone and Methadone as well as others. While they have been widely used to help patients manage pain, the numerous harmful side effects and high potential for addiction have created more problems than solutions for many patients. Opiate use can cause respiratory depression, seizures, heart failure, and even pain sensitivity as well as a long list of other side effects. Overuse and abuse can lead to coma and even death.
The chance of addiction with Mitragyna Speciose is significantly lower than that of opiates, and there are far fewer (and milder) side effects. These side effects may include dizziness, facial flushing, nausea, constipation, vomiting, and sweating. However, when compared to the effects of opiates, this substance is a superior pain solution. As Health Advance, Inc. moves forward with its clinical trials, it appears as though chronic pain patients may soon get a safer, healthier option for managing their pain.
Health Advance, Inc. is a U.S. based corporation operating as a global manufacturer and sales distributor of nutritional and pharmaceutical solutions. The company recently acquired Hantian Labs, a U.K. based company Hantian Labs (hantianlabs.com) which is an emerging global leader in anti-aging and vitality nutraceutical products. Additionally, the Company is an on-line retailer of home medical products with operations in Canada and the United States, and with administration and infrastructure supported globally.